The Enterprise Value as of December 2024 (TTM) for Apellis Pharmaceuticals, Inc. (APLS) is 4.20B

According to Apellis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.20B. This represents a change of -25.97% compared to the average of 5.68B of the last 4 quarters.

Apellis Pharmaceuticals, Inc. (APLS) Historical Enterprise Value (quarterly & annually)

How has APLS Enterprise Value performed in the past?

The mean historical Enterprise Value of Apellis Pharmaceuticals, Inc. over the last ten years is 2.27B. The current 4.20B Enterprise Value has changed 18.42% with respect to the historical average. Over the past ten years (40 quarters), APLS's Enterprise Value was at its highest in in the June 2023 quarter at 10.36B. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.

Apellis Pharmaceuticals, Inc. (APLS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Apellis Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Apellis Pharmaceuticals, Inc. (APLS) Average Enterprise Value

How has APLS Enterprise Value performed in the past?

The current Enterprise Value of Apellis Pharmaceuticals, Inc. (APLS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Apellis Pharmaceuticals, Inc. (APLS) Enterprise Value vs. Peers

How is APLS’s Enterprise Value compared to its peers?

Apellis Pharmaceuticals, Inc.’s Enterprise Value is less than Prometheus Biosciences, Inc. (9.30B), greater than Akero Therapeutics, Inc. (1.70B), greater than Immunovant, Inc. (3.31B), less than Madrigal Pharmaceuticals, Inc. (6.67B), greater than Day One Biopharmaceuticals, Inc. (859.59M), greater than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (209.72M), greater than Terns Pharmaceuticals, Inc. (234.86M), greater than X4 Pharmaceuticals, Inc. (79.21M), greater than Inozyme Pharma, Inc. (215.58M), greater than Mereo BioPharma Group plc (445.16M), less than Blueprint Medicines Corporation (6.12B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Acumen Pharmaceuticals, Inc. (103.15M),

Build a custom stock screener for Apellis Pharmaceuticals, Inc. (APLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apellis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Apellis Pharmaceuticals, Inc. (APLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Apellis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.